Activation and blocking of 5-HT1A receptors influence on the immune response in CBA mice

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 68, Issue 1, 2005, Pages 42-44

  Idova, G V ^a   Cheido, M A ^a   Davydova, S M ^a  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL) CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ERYTHROCYTE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; MOUSE STRAIN; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; ERYTHROCYTES; MALE; MICE; MICE, INBRED CBA; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; SHEEP;

EID: 15044361671     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. T. M. Aune, K. M. McGrath, T. Sarr, et al., J. Immunol., 151(3), 1175-1183 (1993).
2. N. M. Barnes and T. A. Sharp, Neuropharmacology, 38, 1083-1152 (1999).
3. D. J. Critchey, K. J. Childs, V. C. Maddlefell, and C. T. Dourish, Eur. J. Pharmacology., 264, 95-97 (1994).
4. A. J. Cunningham, Nature, 207, 1106-1107 (1965).
5. L. V. Devoino and G. V. Idova, Eur. J. Pharmacol., 22, 325-331 (1973).
6. R. M. Eglen, J. R. Jasper, D. J. Chang, and J. R. Martin, Trends Pharmacol. Sci., 18, 104-107 (1997).
7. A. Fletcher, E. A. Forster, D. J. Bill, et al., Behav. Brain. Res., 73(1-2), 337-353 (1996).
8. E. Gur, E. Dremencov, and D. E. Van, Eur. J. Pharmacol., 436(1-2), 57-65 (2002).
9. R. Hellstrand and S. Hermodsson, Scand. J. Immunol., 37(1), 7-18 (1993).
10. K. Iken, S. Chheng, A. Fargin, et al., Cell Immunol., 163(1), 1-9 (1995).
11. T. C. Pellegrino and B. M. Bayer, Brain. Behav. Imm., 16, 87-103 (2002).
12. F. Serres, N. A. Muma, D. K. Raap, et al., J. Pharmacol. Exp. Ther., 294(1), 296-301 (2000).
13. J. Stefulj, B. Jernej, and L. Cicin-Sain, et al., Brain. Behav. Imm., 14(3), (2000).
14. J. Yamada, Y. Sugimoto, and K. Horisaka, Eur. J. Pharmacol., 154(3), 299-304 (1988).